CNBX Pharmaceuticals Inc. (CNBX)

CNBX Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Revenue	-	0.13	0.41	0.03	-
Revenue Growth (YoY)	-	-68.29%	1269.13%	-	-
Gross Profit	-	0.13	0.41	0.03	-
Selling, General & Admin	0.27	0.52	0.91	1.8	0.83
Research & Development	-	0.19	0.43	1.18	1.77
Operating Expenses	0.27	0.71	1.34	2.98	2.6
Operating Income	-0.27	-0.58	-0.93	-2.95	-2.6
Interest Expense	-0.04	-0.02	-0	-0	-0
Currency Exchange Gain (Loss)	-0	-0	0	-0.06	-0.02
Other Non Operating Income (Expenses)	-	-	-0.05	-0.72	-0.96
EBT Excluding Unusual Items	-0.31	-0.61	-0.98	-3.74	-3.59
Gain (Loss) on Sale of Investments	-	-	-	-	0.2
Gain (Loss) on Sale of Assets	-	-0.09	-2.73	0.01	0.2
Pretax Income	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income to Common	-0.31	-0.7	-3.71	-3.72	-3.19
Shares Outstanding (Basic)	91	30	9	1	1
Shares Outstanding (Diluted)	91	30	9	1	1
Shares Change (YoY)	199.69%	242.76%	621.77%	5.92%	2.95%
EPS (Basic)	-0.00	-0.02	-0.42	-3.05	-2.77
EPS (Diluted)	-0.00	-0.02	-0.42	-3.05	-2.77
Free Cash Flow	-0.17	-0.25	-0.11	-1.68	-2.49
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-1.38	-2.16
Gross Margin	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-448.31%	-227.07%	-9860.37%	-
Profit Margin	-	-534.46%	-904.57%	-12428.23%	-
Free Cash Flow Margin	-	-188.71%	-27.43%	-5610.68%	-
EBITDA	-0.2	-0.51	-0.77	-2.76	-2.38
EBITDA Margin	-	-	-187.56%	-	-
D&A For EBITDA	0.07	0.07	0.16	0.2	0.22
EBIT	-0.27	-0.58	-0.93	-2.95	-2.6
EBIT Margin	-	-	-227.07%	-	-

Updated Aug 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.